Ovid Therapeutics Inc.
OVID· Nasdaq
Released May 14, 2024, before the open
10-Q filed May 14, 2024, 44 days after period end · 0001628280-24-023067
| Metric | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|
| Revenue | $148.00K | $66.00K | $1.45M | $208.38M |
| Net Income | -$11.69M | -$13.36M | -$16.11M | $176.01M |
| EPS Diluted |
Ovid Therapeutics Inc. · CIK 1636651 · Engraved from SEC EDGAR
| -$0.17 |
| -$0.19 |
| -$0.23 |
| $2.53 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.